Search research articles
Contact Us
Filters
Showing results (51-60 of 103) with videos related to
Page
of 11
Sort By:
Circulation. Cardiovascular Interventions
|
September 24, 2025
Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation
Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
December 8, 2022
Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome - A Post Hoc Secondary Analysis of STOPDAPT-2 ACS
Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, et al.
JACC. Asia
|
November 27, 2025
Effect of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention With Aspirin-Free Strategy
Tenjin Nishikura, Ko Yamamoto, Kohei Wakabayashi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
October 24, 2024
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial
Ko Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
January 25, 2025
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial
Takenori Domei, Ko Yamamoto, Masahiro Natsuaki, et al.
Cardiovascular Intervention and Therapeutics
|
November 13, 2020
Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2
Hirotoshi Watanabe, Takeshi Morimoto, Manabu Ogita, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
March 18, 2026
Aspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes - Prespecified Subgroup Analysis of the STOPDAPT-3 Trial
Kenji Kanenawa, Ko Yamamoto, Takenori Domei, et al.
Circulation
|
November 23, 2023
An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial
Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Cardiovascular Intervention and Therapeutics
|
March 7, 2018
Mortality impact of post-discharge myocardial infarction size after percutaneous coronary intervention: a patient-level pooled analysis from the 4 large-scale Japanese studies
Hirotoshi Watanabe, Takeshi Morimoto, Hiroki Shiomi, et al.
JACC. Cardiovascular Interventions
|
January 4, 2023
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention
Ko Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Page
of 11
Search research articles
Search
Showing results (51-60 of 103) with videos related to
Sort By:
Page
of 11
Circulation. Cardiovascular Interventions
|
September 24, 2025
Aspirin Versus Clopidogrel Beyond 1 Month After PCI in Patients With Oral Anticoagulation
Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
December 8, 2022
Prevalence and Effects of High-Intensity Statins for Japanese Patients Presenting With Acute Coronary Syndrome - A Post Hoc Secondary Analysis of STOPDAPT-2 ACS
Hirotoshi Watanabe, Takeshi Morimoto, Ko Yamamoto, et al.
JACC. Asia
|
November 27, 2025
Effect of Proton Pump Inhibitors in Patients Undergoing Percutaneous Coronary Intervention With Aspirin-Free Strategy
Tenjin Nishikura, Ko Yamamoto, Kohei Wakabayashi, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
October 24, 2024
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial
Ko Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
January 25, 2025
Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial
Takenori Domei, Ko Yamamoto, Masahiro Natsuaki, et al.
Cardiovascular Intervention and Therapeutics
|
November 13, 2020
Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2
Hirotoshi Watanabe, Takeshi Morimoto, Manabu Ogita, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society
|
March 18, 2026
Aspirin vs. Clopidogrel Monotherapy Beyond 1 Month After Percutaneous Coronary Intervention in Patients With Diabetes - Prespecified Subgroup Analysis of the STOPDAPT-3 Trial
Kenji Kanenawa, Ko Yamamoto, Takenori Domei, et al.
Circulation
|
November 23, 2023
An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial
Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Cardiovascular Intervention and Therapeutics
|
March 7, 2018
Mortality impact of post-discharge myocardial infarction size after percutaneous coronary intervention: a patient-level pooled analysis from the 4 large-scale Japanese studies
Hirotoshi Watanabe, Takeshi Morimoto, Hiroki Shiomi, et al.
JACC. Cardiovascular Interventions
|
January 4, 2023
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Patients With Diabetes Undergoing Percutaneous Coronary Intervention
Ko Yamamoto, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Page
of 11